HSHiroki Saito

Hiroki Saito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroki Saito has a total of 230 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eritoran and apremilast in hospitalized patients with COVID-19: The REMAP-CAP immune modulation-2 domain

    by Hiroki Saito, Farah Al-Beidh, Derek Angus, Djillali Annane, Yaseen Arabi, Abigail Beane, Lindsay Berry, Scott Berry, Zahra Bhimani, Janis Best-Lane, et al.

  • Open Access

    A scoping review of randomized controlled trials in the early phase of the COVID-19 pandemic: country-level research response to COVID-19 therapeutics and vaccines

    by Hiroki Saito, Mai Inada, Satoshi Miike, Minoru Yoshida, Shinya Tsuzuki, Yasunori Ichimura, Uiri Ohki, Nobuhiko Kimura, Itsuro Yoshimi, Kei Kawano, et al.

    Clinical trials are central in pandemic preparedness and response (PPR). This scoping review aimed to illustrate the landscape of COVID-19-related randomiz

  • Open Access

    Views on consent approaches used in emergency and critical care research: a rapid, systematic review

    by Niamh Mahon, Leanne M. C. Hays, Eva Coy, Kate Ainscough, Aidan Burrell, Anthony C. Gordon, Bram Rochwerg, Chun-Mei Wang, Dan Harvey, Dhruv Parekh, et al.

    Obtaining informed consent can be challenging in emergency and critical care research due to the acute and severe nature of the patient’s condition.


  • Open Access

    What did trial participants in REMAP-CAP Japan experience during the COVID-19 pandemic? A qualitative study

    by Yumiko Oyama, Hiroki Saito, Yuiko Hoshina, Naoaki Ichihara, Kazuaki Jindai

    Informed consent is crucial for clinical trial participation. However, there have been no qualitative studies of participants’ experiences in randomi


  • First Train-the-Trainers in Hand Hygiene in Uganda: a multilevel evaluation

    by B. Aber, E. Nyawere, F. Owori, E. Tartari, C. Fankhauser, H.M. Villarreal, H. Saito, D. Pittet


  • Open Access

    Building an international precision medicine platform trial for the acute respiratory distress syndrome (ARDS): an expert consensus project report

    by Kiran Reddy, Neil Aggarwal, Narges Alipanah-Lechner, Djillali Annane, David B Antcliffe, Daphne Babalis, J Kenneth Baillie, Abigail Beane, Lieuwe Dj Bos, Aidan Burrell, et al.

    Background: Almost all large-scale trials of disease-modifying therapeutic agents in critical care have failed to show benefit for patients, which may be explained in part by the clinical and biological heterogeneity inherent in virtually all critical illness syndromes. Enrichment strategies have been developed to separate responders from non-responders and better target treatments. In patients with the acute respiratory distress syndrome, a critical illness syndrome involving severe lung inflammation, latent class analysis and other clustering approaches have led to the discovery of subgroups (phenotypes) that appear to respond differently to treatment based on retrospective analyses of published clinical trials and observational cohorts. The next step is to test these phenotypes in a prospective trial. Rapid, point-of-care analytical methods have now made such a trial possible. There is a need to advance treatment for patients with acute respiratory distress syndrome and other critical illness syndromes by incorporating a phenotype-based approach into prospective trial design. The hyperinflammatory and hypoinflammatory phenotypes, that have been identified in acute respiratory distress syndrome, will be the first to be included in such a trial, with scope for further phenotypes to be studied over time. Future work: This Efficacy and Mechanism Evaluation report, through expert consensus, describes a new Phase II, multiarm, adaptive platform randomised controlled trial design that tests multiple pharmacological therapies in a population of patients with acute respiratory distress syndrome stratified by baseline inflammatory phenotype. This report also reviews issues to be considered in developing precision medicine trials in critical care, which are designed with newly developed clinical phenotypes in mind. This work has been used to develop the Precision medicine Adaptive Network platform Trial in Hypoxaemic acutE respiratory failuRe precision medicine trial in acute respiratory distress syndrome, which has been funded and will begin recruitment in June 2025. Limitations: This report is the result of expert consensus review, rather than utilising strict review methodologies (e.g. Delphi consensus process). However, expert consensus has been found to generate similar results to consensus processes when a high degree of agreement is reached and > 70% agreement was reached for all included recommendations. Funding: This article presents independent research funded by the (NIHR) Efficacy and Mechanism Evaluation programme as award number NIHR154493.


  • Open Access

    Principal investigators’ experience of COVID-19 therapeutic clinical trials in Japan: a qualitative study

    by Satoko Horii, Hiroki Saito, Taro Shibata, Miwa Sonoda, Tatsuo Iiyama, Kazuaki Jindai

    Objective: During the COVID-19 pandemic, many clinical trials were conducted to identify effective COVID-19 therapeutics. However, while a large amount of resources was invested and significant numbers of patients participated, this did not necessarily have an impact on clinical practice. To face these issues, initiatives such as the 100 Days Mission have been set out globally. Yet, limited data exist on the context surrounding the implementation of clinical trials at a national level during a health emergency. The study explored experiences and perceptions of principal investigators in conducting clinical trials for COVID-19 therapeutics in Japan. Design: A qualitative study was conducted using semistructured interviews. The obtained data were inductively analysed using thematic analysis. Setting and participants: We interviewed 15 principal investigators between September and November 2022 who conducted investigator-initiated clinical trials on the development of COVID-19 therapeutics in Japan. Results: Three themes were generated: structural barriers , fragmented efforts and limited evidence generation . Structural barriers and fragmented efforts comprised four subthemes: individual, institutional, interinstitutional and policy/regulatory levels. Structural barriers at all levels included (1) limitations of individual capabilities, (2) the double burden of clinical practice and research, (3) inefficient interinstitutional collaboration and (4) regulatory frameworks and available resources that interrupt stakeholders’ actions, leading to limited evidence generation despite the fragmented efforts of principal investigators and other stakeholders. Conclusions: This study illustrated that the efforts of Japanese principal investigators did not necessarily pay off in identifying therapeutics. A strategic and systematic approach for an improved national clinical trial ecosystem must be sought during the interpandemic period to overcome structural barriers in harmonisation with the global stakeholders.


  • Open Access

    How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings

    by Hiroki Saito, Kazuaki Jindai, Taro Shibata, Miwa Sonoda, Tatsuo Iiyama

    The COVID-19 pandemic posed a serious challenge to national and global pandemic preparedness and response (PPR). Timely identification and development of diagnostics, therapeutics and vaccines through prompt evidence generation from clinical trials was recognized as an important health security agenda. In 2022, under the guidance of Japan Ministry of Health, Labour and Welfare (MHLW), a health policy research team was convened to analyze the COVID-19 related clinical trial ecosystem in the context of PPR in Japan and abroad with a focus on clinical trials for therapeutics. The research mainly composed of the following: a narrative review of relevant peer reviewed journals and grey literature, interview of global experts and stakeholders including those from the United States and the United Kingdom, and a culminating meeting in Japan with various stakeholders. Based on the outcomes of this research, the team makes the following three recommendations: (1) Strengthen the leadership group's role in infectious disease clinical trials, (2) Promote sustained coordination and collaboration among stakeholders, and (3) Apply innovative clinical trial designs and create an enabling research environment. Clinical trials, as a public health good, must be further integrated into healthcare. The team advocates for the implementation of these recommendations at the policy level to help improve the clinical trial ecosystem for future health emergencies in Japan.


  • Open Access

    Sepsis in Global Health: Current global strategies to fight against sepsis

    by Hiroki Saito

    Sepsis is prevalent globally, causing a significant disease burden in global health. Sepsis is a complex disease condition, and therefore, the effective strategies to overcome sepsis need to be set up in layers across different sectors and populations. Over the years, the global society has been making progress in addressing sepsis as a public health threat. This review aims to examine and describe the current sepsis strategies globally and to sustain the fight against sepsis in the context of global health.


  • Open Access

    Transmission of MRSA, ESBL E. coli, and C. difficile within a tertiary care hospital and across surrounding facilities in Japan: a molecular epidemiological study with the PCR-based Open-reading frame typing

    by Hiroki Saito, Satoshi Miike, Tatsuya Ohno, Momoko Anzai, Fumimasa Kasai, Akiko Hosoyama, Tomomi Takakura, Yosuke Tanaka, Shigeki Fujitani

    Objective: To determine the regional impact of transmission of multidrug-resistant organisms (MRDOs) and Clostridioides difficile (C. difficile) among a tertiary care hospital and surrounding facilities including long-term care facilities (LTCFs).Design: Retrospective cohort study.Methods: Patients admitted to a tertiary care hospital from July 2019 to July 2021 were recruited if their clinically collected cultures grew the following pathogens: Methicillin-resistant Staphylococcus aureus (MRSA), Extended-Spectrum Beta-Lactamase (ESBL) producing Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, Carbapenem-resistant Enterobaterales, Vancomycin-resistant Enterococci, and C. difficile. Patient characteristics including admission and discharge pathway were collected. For the isolates of MRSA, ESBL-producing Escherichia coli (E. coli), and C. difficile, a molecular epidemiological analysis was conducted, utilizing the PCR-based Open-Reading Frame Typing (POT) method.Results: Three hundred-five patients were identified with a total of 332 culture specimens of the target pathogens. The top three were 132 MRSA isolates (43.3%, out of 305), 97 ESBL E. coli (31.8%), and 32 ESBL Enterobacterales (non-E. coli) (10.5%). The target pathogens were more detectable within 3 days among patients admitted from LTCFs or other hospitals than those admitted from home (Odds Ratio 4.6, 95% confidence interval 2.8-7.6, p-value < 0.001). The molecular epidemiological analysis suggested the transmissions of MRSA, ESBL E. coli and C. difficile occurred 52 out of 111 patients within the in-hospital environment, and 7 out of 128 within the prehospital environment, respectively.Conclusions: MDROs/C. difficile transmission is prevalent within a tertiary care hospital and further complicated by its inter-facility transmission across surrounding LTCFs and hospitals in Japan.